Targeting therapeutic oligonucleotides
AA Levin - New England Journal of Medicine, 2017 - Mass Medical Soc
New England Journal of Medicine, 2017•Mass Medical Soc
Targeting Therapeutic Oligonucleotides | NEJM Skip to main content NEJM Group Follow Us
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your
knowledge, lead a health care organization, and advance your career with NEJM Group
information and services. NEJM Evidence NEW! A digital journal for innovative original research
and fresh, bold ideas in clinical trial design and clinical decision-making. NEJM Catalyst NEW!
Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care …
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your
knowledge, lead a health care organization, and advance your career with NEJM Group
information and services. NEJM Evidence NEW! A digital journal for innovative original research
and fresh, bold ideas in clinical trial design and clinical decision-making. NEJM Catalyst NEW!
Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care …
Two recent studies test whether oligonucleotide drugs that are tailored to target different cell types — the hepatocyte and the myocyte and cardiomyocyte — actually target those cell types.
The New England Journal Of Medicine